How to buy Albireo Pharma stock (ALBO)

Albireo Pharma is a biotechnology business based in the US. Albireo Pharma shares (ALBO) are listed on the NASDAQ and all prices are listed in US Dollars. Albireo Pharma employs 130 staff and has a trailing 12-month revenue of around $57.4 million.

Our top picks for where to buy Albireo Pharma stock

Buy Albireo Pharma stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Albireo Pharma stock price (NASDAQ: ALBO)

Use our graph to track the performance of ALBO stocks over time.

Albireo Pharma shares at a glance

• Key figures

Information last updated 2024-06-30.

52-week range	$0.00 - $0.00
50-day moving average more info button	$38.96
200-day moving average more info button	$25.30
Wall St. target price	$42.00
PE ratio more info button	N/A
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$-6.66

Is it a good time to buy Albireo Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Albireo Pharma financials

Revenue TTM	$57.4 million
Gross profit TTM	$39.2 million
Return on assets TTM	-24.94%
Return on equity TTM	-93.08%
Profit margin	-228.51%
Book value	$4.84
Market Capitalization more info button	$915.9 million

TTM: trailing 12 months

Albireo Pharma share dividends

We're not expecting Albireo Pharma to pay a dividend over the next 12 months.

Have Albireo Pharma's shares ever split?

Albireo Pharma's shares were split on a 1:30 basis on 3 November 2016 . So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Albireo Pharma shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Albireo Pharma shares which in turn could have impacted Albireo Pharma's share price.

Albireo Pharma share price volatility

Over the last 12 months, Albireo Pharma's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Albireo Pharma's is 1.0356. This would suggest that Albireo Pharma's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Albireo Pharma overview

Albireo Pharma, Inc. , a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co. , Ltd. for the development and commercialization of elobixibat.

Frequently asked questions

null
What percentage of Albireo Pharma is owned by insiders or institutions?
Currently 3.61% of Albireo Pharma shares are held by insiders and 107.689% by institutions. How many people work for Albireo Pharma?
Latest data suggests 130 work at Albireo Pharma. When does the fiscal year end for Albireo Pharma?
Albireo Pharma's fiscal year ends in December. Where is Albireo Pharma based?
Albireo Pharma's address is: 10 Post Office Square, Boston, MA, United States, 02109 What is Albireo Pharma's ISIN number?
Albireo Pharma's international securities identification number is: US01345P1066 What is Albireo Pharma's CUSIP number?
Albireo Pharma's Committee on Uniform Securities Identification Procedures number is: 09064M105